Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 3/20 | 0.50 |
| ▸ | CDK8 | P49336 | 3/20 | 0.50 |
| ▸ | SLC22A12 | Q96S37 | 6/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 3/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.40 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16212140 | 0.90 | CCNC (0.53) | CCNCCDK8SLC22A12CNR1SERPINE1 | |
| SCHEMBL16222216 | 0.84 | CCNC (0.50) | CCNCCDK8SLC22A12GABRA5CNR1 | |
| SCHEMBL10138554 | 0.83 | CCNC (0.68) | CCNCCDK8SLC22A12RAB9ASERPINE1 | |
| SCHEMBL10138555 | 0.83 | CCNC (0.53) | CCNCCDK8SLC22A12CNR1SERPINE1 | |
| SCHEMBL16211724 | 0.81 | CCNC (0.53) | CCNCCDK8SLC22A12GABRA5 | |
| SCHEMBL16212201 | 0.80 | CCNC (0.47) | CCNCCDK8SLC22A12GABRA5SERPINE1 | |
| SCHEMBL18731277 | 0.79 | CCNC (0.51) | CCNCCDK8SLC22A12SERPINE1 | |
| SCHEMBL15743094 | 0.79 | CCNC (0.49) | CCNCCDK8SLC22A12GABRA5CNR2 | |
| SCHEMBL18731268 | 0.78 | CCNC (0.48) | CCNCCDK8SLC22A12NPC1RAB9A | |
| SCHEMBL16211923 | 0.78 | CCNC (0.46) | CCNCCDK8SLC22A12SERPINE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2991635-B1 | NEUROGENESIS-STIMULATING ISOQUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-04-12 | — | — | EP | claimed |
| US-9586903-B2 | Isoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-03-07 | — | — | US | claimed |
| EP-2991635-A1 | NEUROGENESIS-STIMULATING ISOQUINOLINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2016-03-09 | — | — | EP | claimed |
| US-20160046583-A1 | ISOQUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-02-18 | — | — | US | claimed |
| WO-2014177596-A1 | NEUROGENESIS-STIMULATING ISOQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-11-06 | — | — | WO | claimed |
| EP-2991635-B1 | NEUROGENESIS-STIMULATING ISOQUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-04-12 | — | — | EP | disclosed |
| EP-2991635-B1 | NEUROGENESIS-STIMULATING ISOQUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-04-12 | — | — | EP | disclosed |
| US-9586903-B2 | Isoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586903-B2 | Isoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586903-B2 | Isoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| EP-2991635-A1 | NEUROGENESIS-STIMULATING ISOQUINOLINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2016-03-09 | — | — | EP | disclosed |
| US-20160046583-A1 | ISOQUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160046583-A1 | ISOQUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160046583-A1 | ISOQUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-02-18 | — | — | US | disclosed |
| WO-2014177596-A1 | NEUROGENESIS-STIMULATING ISOQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014177596-A1 | NEUROGENESIS-STIMULATING ISOQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046583-A1 | ISOQUINOLINE DERIVATIVES | CDR2, DRD2, HCRTR1 | CCNC 945/4885CDK8 3480/4885SLC22A12 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.